Evidence map›Paper›PMID 31182926›Full record

ArticleInternational journal of biological sciences2019

Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis.

Pengfei Qi, Yanli Li, Xiaomin Liu, Fatemeh A Jafari, Xinju Zhang, Qiangling Sun, Zhongliang Ma

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. A Review of Cryptotanshinone and its Nanoformulation in Cancer Therapy.Anti-cancer agents in medicinal chemistry · 2025
    Review
  7. Article
  8. Article
  9. Experimental and therapeutic medicine · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Frontiers in pharmacology · 2022
    Review
  15. Article
  16. Article
  17. Clinico-Pathological Importance of miR-146a in Lung Cancer.Diagnostics (Basel, Switzerland) · 2021
    Review
  18. Article
  19. MicroRNA-486-5p Suppresses Lung CancerFrontiers in oncology · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pengfei QiLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Yanli LiLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Xiaomin LiuLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Fatemeh A JafariLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Xinju ZhangLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Qiangling SunDepartment of Thoracic Surgery, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China.
Zhongliang MaLab for Noncoding RNA & Cancer, School of Life Sciences, Shanghai University, Shanghai, China.
Shanghai University · CNShanghai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR), a cancer-driven gene, plays an important role in tumorigenesis of lung cancer. Cryptotanshinone (CT) is the main constituent of

Indexed as

A549 CellsCarcinoma, Non-Small-Cell LungCell CycleCell Line, TumorCell ProliferationErbB ReceptorsHEK293 CellsHumansImmunoblottingMicroRNAsPhenanthrenescryptotanshinoneEGFR protein, humanErbB ReceptorsMicroRNAsMIRN146 microRNA, humanPhenanthrenescryptotanshinoneEGFRmiR-146a-5pNSCLC

Identifiers

PMID31182926
PMCPMC6535795
OpenAlexW2947589269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.